31.44

4.96% -1.64

After Hours: 31.66 0.22 +0.70%

Vericel Corp (VCEL)

Overview News Price History Option Chain Financials Discussions Forecast Stock Split

Vericel Corp stock is traded at $31.44, with a volume of 2.02M. It is down -4.96% in the last 24 hours and down -15.23% over the past month. Vericel Corp is a fully integrated commercial-stage biopharmaceutical company and a provider of therapies for the sports medicine and severe burn care markets. It markets cell therapy products in the United States, MACI (autologous cultured chondrocytes on porcine collagen membrane); Epicel (cultured epidermal autografts); and NexoBrid. The Company operates its business in the U.S. in one reportable segment; the research, product development, manufacture, and distribution of cellular therapies and specialty biologics for use in the treatment of specific conditions.

Previous Close:

$33.08

Open:

$33.47

24h Volume:

2.02M

Relative Volume:

3.60

Market Cap:

$1.60B

Revenue:

$276.26M

Net Income/Loss:

$16.52M

P/E Ratio:

102.14

EPS:

0.3078

Net Cash Flow:

$24.75M

1W Performance:

-2.66%

1M Performance:

-15.23%

6M Performance:

+5.36%

1Y Performance:

-34.45%

1-Day Range:

$30.67

$33.63

1-Week Range:

$30.67

$34.34

52-Week Range:

$29.24

$47.74

Vericel Corp Stock (VCEL) Company Profile

Name

Vericel Corp

Sector

Healthcare (1114)

Industry

Biotechnology (623)

Phone

(734) 930-5555

Address

64 SIDNEY ST., CAMBRIDGE, MA

Employee

398

Twitter

@VericelCorp

Next Earnings Date

2024-11-07

Latest SEC Filings

VCEL's Discussions on Twitter

Compare VCEL vs VRTX, REGN, ALNY, ARGX, INSM

Stocks	Price	Market Cap	Revenue	Net Income	Cash Flow	EPS
VCEL Vericel Corp	31.44	1.68B	276.26M	16.52M	24.75M	0.3078
VRTX Vertex Pharmaceuticals Inc	454.97	113.96B	12.07B	3.95B	3.19B	15.33
REGN Regeneron Pharmaceuticals Inc	749.47	78.41B	14.34B	4.50B	3.77B	41.56
ALNY Alnylam Pharmaceuticals Inc	328.70	40.85B	3.71B	313.75M	465.38M	2.2571
ARGX Argen X Se Adr	697.05	42.05B	4.16B	1.29B	734.26M	19.58
INSM Insmed Inc	148.31	29.99B	606.42M	-1.28B	-997.58M	-6.403

Vericel Corp Stock (VCEL) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
Sep-17-25	Downgrade	BTIG Research	Buy → Neutral
Aug-09-24	Initiated	Canaccord Genuity	Buy
Jun-20-24	Initiated	TD Cowen	Buy
Jan-25-24	Upgrade	Truist	Hold → Buy
Aug-08-23	Upgrade	BTIG Research	Neutral → Buy
Nov-10-22	Downgrade	BTIG Research	Buy → Neutral
Nov-09-22	Downgrade	Truist	Buy → Hold
Oct-14-22	Resumed	Stephens	Overweight
Jan-11-21	Downgrade	Oppenheimer	Outperform → Perform
Dec-18-20	Initiated	Stephens	Overweight
Sep-17-20	Initiated	Truist	Buy
Oct-09-19	Initiated	H.C. Wainwright	Buy
Feb-28-19	Downgrade	Needham	Buy → Hold
Aug-08-18	Reiterated	Needham	Buy
Jul-16-18	Upgrade	Ladenburg Thalmann	Neutral → Buy
Apr-04-18	Initiated	Leerink Partners	Outperform
Mar-06-18	Downgrade	Ladenburg Thalmann	Buy → Neutral
Mar-06-18	Reiterated	Needham	Buy
Mar-05-18	Reiterated	BTIG Research	Buy
Jun-21-17	Initiated	BTIG Research	Buy
Mar-13-17	Reiterated	Needham	Buy
Dec-22-16	Initiated	Piper Jaffray	Overweight
Nov-09-16	Reiterated	Needham	Buy
Apr-05-16	Downgrade	BofA/Merrill	Buy → Neutral
Mar-11-16	Upgrade	Needham	Hold → Buy

View All

Vericel Corp Stock (VCEL) Latest News

Mar 25, 2026

Vericel Corporation $VCEL Position Increased by Congress Asset Management Co. - MarketBeat

Mar 24, 2026

Mar 23, 2026

[144] Vericel Corp SEC Filing - Stock Titan

Mar 23, 2026

Mar 19, 2026